BACKGROUND
hemangiomas in patients with the Ollier disease and Maffuci syndrome, non-hereditary skeletal disorders (11) .
More recent DNA resequencing projects have provided additional information regarding the timing of IDH mutations during tumor development. Analyzing over 300 gliomas, Watanabe et al. found that in 51 cases with multiple biopsies, neither acquisition of a mutation in TP53 nor loss of 1p/19q occurred prior to a mutation in IDH1 (12) . Further analysis of matched biopsy pairs, collected from glioma patients at the initial diagnosis and the time of tumor recurrence showed that IDH1 R132H was the only mutation that was consistently present in both the initial and recurrent biopsy specimen (13) . In leukemia patients, IDH2 mutations were observed in the absence of NPM1c mutations in both mature and progenitor cell populations, suggesting that IDH2 mutation might be an early and perhaps pre-leukemic event (14, 15) .
The vast majority of cancer-associated mutations in IDH1 and IDH2 map to an arginine within the catalytic pocket of the enzyme. Mutations in IDH1 mostly occur at arginine 132, with substitutions including R132H, R132C, R132L, R132S and R132G. Mutations in IDH2 typically occur at arginine 172 or arginine 140 (which is analogous to R132 in IDH1). The clustering of cancer-associated IDH mutations in the functional domain of the enzyme suggested that these mutations might endow the mutant protein with a novel and presumably oncogenic enzymatic activity. This question has been explored through untargeted metabolomic profiling of cells engineered to express the mutant enzyme. Compared to parental cells, cells expressing the IDH1 R132H mutant enzyme were found to produce the R(-) enantiomer of the metabolite 2-hydroyglutarate (R-2-HG), which accumulates in IDH mutant human gliomas (16) and leukemias (5, 17) . Production of R-2-HG involves direct conversion from α-KG and relies on the presence of a wild type allele (18) , likely explaining the rareness of loss of heterozygosity.
The identification of an 'oncometabolite" in IDH mutant tumors strengthened the hypothesis that IDH mutations are oncogenic, and led many investigators to examine the ability of mutant IDH to transform non-malignant cells. Expression of mutant Idh in mouse myeloid progenitor 32D cells and primary mouse bone marrow cells impaired hematopoietic differentiation and increased stem/progenitor cell marker expression, suggesting a pro-leukemogenic effect (19) . A more recent study reported that retrovirally mediated expression of mutant Idh2 R140Q in murine primary hematopoeitic bone marrow stem and progenitor cell populations induced myeloproliferative-like neoplasms, T-cell lymphoma or B-cell lymphoma when transplanted into irradiated mice (20) . However, these hematological malignancies occurred at low penetrance and with long latency, suggesting that they did not arise solely due to mutant /Meis1a-driven leukemia cells (24) .
CLINICAL-TRANSLATIONAL ADVANCES
The above mentioned results in experimental leukemia models are supported by the preliminary findings 
endogenous mutant IDH1 gene using TALEN technology similarly impaired anchorage-independent growth and in-vivo growth of IDH-mutant human sarcoma cells (41) . In IDH1 mutant glioma cells, pharmacological blockade of the mutant enzyme retarded their growth in soft-agar and in mice (42) .
Targeted therapy of IDH mutant cancers is likely to grow beyond inhibition of the mutant enzyme itself and may include strategies directed against the epigenetic and metabolic changes that are associated with IDH mutations. Current data suggests that the R-2-HG 'oncometabolite' is responsible for many, if not all, biological effects of cancer-associated IDH mutations. Cell-permeable esters of R-2-HG phenocopy the effects of mutant IDH in a range of experimental models (43) and ectopic expression of the dehydrogenase (44) that converts R-2-HG into α-KG and thus counteracts the activity of the mutant IDH enzyme is sufficient to reverse the cellular effects of cancer-associated IDH mutants (45) . R-2-HG competitively inhibits a large family of α-KG-dependent enzymes, a protein family with over 60 members. These include the ten-eleven translocation (TET) family of 5-methyl cytosine hydroxylases, the jumonji domain containing (JmjC) family of histone lysine demethylases (46, 47), enzymes involved in nucleic acid metabolism (AlkB, FTO), and many enzymes with still unknown functions (48) (Figure 2 ).
It is currently unknown which α-KG-dependent enzymes function as context-dependent tumor suppressors and are inhibited at the relevant R-2-HG concentrations in human tumors. Inhibition of TET2
is likely to mediate the effects of mutant IDH in AML, given the well documented role of TET2 in hematopoietic differentiation, the almost completely mutual exclusivity of TET2 and IDH mutations in AML (Figure 1) , the decreased 5-hydroxymethylcytosine levels in IDH mutant AMLs, and the identification of TET2 as candidate effector of mutant IDH in a short hairpin RNA library screen of α-KG-dependent dioxygenases (19, 37, (49) (50) (51) . Inhibition of the histone demethylases JMJD2A and JMJD2C likely contributes to the effects of mutant IDH on cellular differentiation in many cell lineages.
These enzymes are particularly sensitive to inhibition by R-2-HG (46, 47), and knockdown of Jmjd2C (also known as Kdm4c) was sufficient to phenocopy the effects of mutant Idh on adipocyte differentiation in 3T3-L1 cells (43) . In fact, it seems plausible than many hallmarks of mutant IDH-associated human malignancies, such as restricted cellular differentiation, DNA hypermethylation result from coordinate effects of R-2-HG on DNA and histone methylation (43, 52) . These findings raise the intriguing question 
